直 Japanese PDF Font
  • 弁護士等
  • 業務内容
  • 論文等
  • オフィス
  • 事務所概要
  • 採用情報
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • CAFC控訴審関連ブログ
    • INCONTESTABLE® Blog
    • 出願関連ブログ
  • Events & Webinars
  • 知財最新ニュース
  • ポッドキャスト
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Seminar

More Practical Advice for Overcoming Inventive Step Rejections at the EPO and the USPTO in the Chemical and Life Sciences Industries

September 17, 2014

London, United Kingdom

Following on the inventive step vs. obviousness webinar from earlier this year, this seminar will focus specifically on the chemical, biotechnology and pharmaceutical industries.

The requirements for inventive step in Europe and non-obviousness in the United States have many similarities but also some subtle differences. In most cases, you might expect similar results, but in some cases, you can end up with very different and unexpected outcomes. With global patenting strategies, companies often struggle to ensure consistency when prosecuting applications to grant in both jurisdictions. In this seminar, we shall look closely at obviousness at the U.S. Patent and Trademark Office (USPTO), inventive step at the European Patent Office (EPO), how they are both assessed and how objections can be overcome in the chemical, pharmaceutical, and biotechnology areas. Our panel will explore:

  • What works for combating objections at these patent offices
  • Why what works at one may not necessarily work at the other
  • Strategies that can work at both
  • Additional approaches to consider in each jurisdiction

The panel will also discuss some of the techniques and strategies they have successfully implemented for patenting chemical and life sciences inventions, often in crowded art fields, including:

  • The lead compound/product analysis
  • Developing a cogent theory of lack of reasonable expectation of success
  • The use of secondary considerations, such as: 
    • comparative testing establishing unexpectedly beneficial results 
    • long-felt but unresolved need 
    • commercial success
  • Plus many other tips and practical advice

Admission is free, but space is limited. Please register by 12 September.

Moderator: 
Anthony C. Tridico, Ph.D.

Speakers: 
Bryan C. Diner
Erin M. Sommers, Ph.D.
Leythem A. Wall

Date:

Wednesday, 17 September 2014

Time:

12:30 - 13:00 - Registration
13:00 - 16:00 - Program
16:00 - 17:00 - Reception

Location:

Finnegan
16 Old Bailey
London EC4M 7EG

Related Practices

グローバルな知的財産権利の執行、訴訟、および裁判

Related Industries

化学

製薬

Related Offices

London

Related Professionals

Bryan C. Diner
Partner
Washington, DC
+1 202 408 4116
Email
Anthony C. Tridico, Ph.D.
Partner
Washington, DC
+1 202 408 4173
Email
Erin M. Sommers, Ph.D.
Partner
Washington, DC
+1 202 408 4292
Email

Related Insights

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Conference

Atlantic Basin Conference on Chemistry 2026

December 6-9, 2026

Rio de Janeiro

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

Broad's 3rd Annual Biotech IP Summit

November 10, 2026

Cambridge

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

Conference

31st Annual UMass Chan Research Retreat

October 15, 2026

Worcester

Webinar

2026 Inventive Step in Europe and the US: Comparing the UPC, EPO and National Approaches

October 14, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • プライバシー
  • 免責事項
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP